secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001819790-26-000037
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus Q1 XDEMVY sales $145.4M (+85% YoY); net loss narrows to $7.0M
--------------------------------------------------------------------

- XDEMVY net product sales $145.4M vs $78.3M YoY; gross margin 94%.
- Reaffirmed FY2026 XDEMVY guidance $670-700M; peak sales potential >$2B.
- Net loss $7.0M ($0.16 loss per share) vs $25.1M loss ($0.64) YoY.
- License fees $16.7M from $15M China regulatory milestone; cash $388.7M.
- Phase 2 Calliope trial started for TP-05 Lyme disease prophylaxis; topline H1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979026000037/0001819790-26-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979026000037/tars-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001819790-26-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer